JP3545408B2 - シャペロニン１０ - Google Patents

シャペロニン１０ Download PDF

Info

Publication number
JP3545408B2
JP3545408B2 JP51529495A JP51529495A JP3545408B2 JP 3545408 B2 JP3545408 B2 JP 3545408B2 JP 51529495 A JP51529495 A JP 51529495A JP 51529495 A JP51529495 A JP 51529495A JP 3545408 B2 JP3545408 B2 JP 3545408B2
Authority
JP
Japan
Prior art keywords
cpn10
epf
rats
serum
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP51529495A
Other languages
English (en)
Japanese (ja)
Other versions
JPH09506431A (ja
Inventor
モートン、ハレ
キャバナフ、アリス・クリスチナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPM8234A external-priority patent/AUPM823494A0/en
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of JPH09506431A publication Critical patent/JPH09506431A/ja
Application granted granted Critical
Publication of JP3545408B2 publication Critical patent/JP3545408B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
JP51529495A 1993-11-30 1994-11-30 シャペロニン１０ Expired - Fee Related JP3545408B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPM270593 1993-11-30
AU2705 1994-09-16
AUPM8234A AUPM823494A0 (en) 1994-09-16 1994-09-16 Diagnostic and therapeutic uses of chaperonin 10
AU8234 1994-09-16
PCT/AU1994/000740 WO1995015338A1 (en) 1993-11-30 1994-11-30 Chaperonin 10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2003319869A Division JP3986481B2 (ja) 1993-11-30 2003-09-11 シャペロニン１０

Publications (2)

Publication Number Publication Date
JPH09506431A JPH09506431A (ja) 1997-06-24
JP3545408B2 true JP3545408B2 (ja) 2004-07-21

Family

ID=25644587

Family Applications (3)

Application Number Title Priority Date Filing Date
JP51529495A Expired - Fee Related JP3545408B2 (ja) 1993-11-30 1994-11-30 シャペロニン１０
JP51529695A Expired - Fee Related JP3987104B2 (ja) 1993-11-30 1994-11-30 シャペロニン１０のアンタゴニスト
JP2003319869A Expired - Fee Related JP3986481B2 (ja) 1993-11-30 2003-09-11 シャペロニン１０

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP51529695A Expired - Fee Related JP3987104B2 (ja) 1993-11-30 1994-11-30 シャペロニン１０のアンタゴニスト
JP2003319869A Expired - Fee Related JP3986481B2 (ja) 1993-11-30 2003-09-11 シャペロニン１０

Country Status (11)

Country Link
US (3) US6113899A (https=)
EP (2) EP0733071A4 (https=)
JP (3) JP3545408B2 (https=)
AT (1) ATE282634T1 (https=)
AU (2) AU684578B2 (https=)
CA (1) CA2177179C (https=)
DE (1) DE69434137T2 (https=)
ES (1) ES2233938T3 (https=)
NZ (2) NZ276670A (https=)
PT (1) PT731811E (https=)
WO (2) WO1995015339A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT731811E (pt) * 1993-11-30 2005-04-29 Univ Queensland Chaperonina 10
JP2001509396A (ja) * 1997-07-10 2001-07-24 メディカル リサーチ カウンシル シャペロン断片
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
CN100406891C (zh) * 2001-06-27 2008-07-30 詹森药业有限公司 利用EPF受体鉴定结合或调节hDRR活性的化合物以及hDRR的分离
AU2002952492A0 (en) 2002-11-06 2002-11-21 Cbio Limited Chaperonin 10 immunosuppression
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
US20070275890A1 (en) * 2004-01-16 2007-11-29 Johnson Barbara J Chaperonin 10 Modulation Of Toll-Like Receptor-Inducible Cytokine And Chemokine Secretion
CN101309934B (zh) 2005-08-31 2014-02-12 悉生物有限公司 修饰的伴侣蛋白10
JP2009511610A (ja) * 2005-10-20 2009-03-19 シービーアイオー リミテッド 過敏症治療
AU2006303826B2 (en) * 2005-10-20 2012-07-19 Cbio Limited Treatment of hypersensitivity
MX2008011167A (es) * 2006-03-02 2008-11-12 Cbio Ltd Regulaciòn de respuestas inmunes mediante la modulaciòn de la funciòn de cèlulas presentadoras de antìgenos.
CA2720617A1 (en) 2008-04-11 2009-10-15 Cbio Limited Modified cpn10 and prr signalling
MX2012004067A (es) * 2009-10-09 2012-08-03 Cbio Ltd Variantes de la chaperonina 10.
US20110243921A1 (en) * 2010-03-30 2011-10-06 Cbio Limited Prevention and treatment of cutaneous lupus erythematosus
KR101776013B1 (ko) * 2017-05-26 2017-09-07 (주)넥스젠바이오텍 항산화 활성 및 피부 세포 증식 효과가 증가한 열 충격 단백질 10과 브라제인 단백질의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2192634B (en) * 1985-03-12 1990-03-21 Univ Queensland Method of detecting early pregnancy factor (epf) in mammals, purifying epf and method for providing a monoclonal antibody
AU599021B2 (en) * 1985-03-12 1990-07-12 University Of Queensland, The Method for detecting early pregnancy factor (epf) in mammals,purifying epf and method for producing a monoclonal antibody
EP0345260A4 (en) * 1986-12-22 1990-05-14 Univ Queensland METHOD FOR TREATING MAMMALS WITH ANTIBODIES AGAINST THE EARLY RECEPTION FACTOR (EPF).
AU1086988A (en) * 1986-12-22 1988-07-15 University Of Queensland, The Method of treatment of mammals using antibodies to early pregnancy factor (epf)
PT731811E (pt) * 1993-11-30 2005-04-29 Univ Queensland Chaperonina 10

Also Published As

Publication number Publication date
JP3986481B2 (ja) 2007-10-03
AU1103495A (en) 1995-06-19
US7358329B2 (en) 2008-04-15
CA2177179A1 (en) 1995-06-08
ATE282634T1 (de) 2004-12-15
EP0731811B1 (en) 2004-11-17
WO1995015339A1 (en) 1995-06-08
EP0733071A4 (en) 1997-02-26
AU684578B2 (en) 1997-12-18
AU684577B2 (en) 1997-12-18
CA2177179C (en) 2006-10-17
AU1103695A (en) 1995-06-19
DE69434137D1 (en) 2004-12-23
ES2233938T3 (es) 2005-06-16
JPH09505811A (ja) 1997-06-10
US20030175280A1 (en) 2003-09-18
EP0731811A1 (en) 1996-09-18
DE69434137T2 (de) 2005-12-01
JP3987104B2 (ja) 2007-10-03
EP0733071A1 (en) 1996-09-25
JPH09506431A (ja) 1997-06-24
NZ276670A (en) 1998-01-26
WO1995015338A1 (en) 1995-06-08
PT731811E (pt) 2005-04-29
NZ276672A (en) 1998-01-26
US6417334B1 (en) 2002-07-09
US6113899A (en) 2000-09-05
JP2004067698A (ja) 2004-03-04
EP0731811A4 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
JP3545408B2 (ja) シャペロニン１０
Manjunath et al. Purification of four gelatin-binding proteins from bovine seminal plasma by affinity chromatography
Nelson et al. Identification of the naturally processed form of hen egg white lysozyme bound to the murine major histocompatibility complex class II molecule I-Ak.
Donoso et al. S-antigen: characterization of a pathogenic epitope which mediates experimental autoimmune uveitis and pinealitis in Lewis rats
Helm et al. Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by a recombinant human epsilon-chain fragment of 76 amino acids.
US4980279A (en) Cellular fibronectin: polypeptides, anti-polypeptide antibodies and assay methods
IBRAHIM et al. Reproductive tract secretions and bull spermatozoa contain different clusterin isoforms that cluster cells and inhibit complement‐induced cytolysis
Beneski et al. Human retinal S-antigen. Isolation, purification, and characterization.
CA2176948C (en) Chaperonin 10
JP3220451B2 (ja) ブタクサからのアレルゲン蛋白質およびそれらの使用
CA2136103C (en) Antibiotic cryptdin peptides and methods of their use
JPH06504667A (ja) 炎症性反応生起に関連するサイトカイン−誘起マーカー
US5698519A (en) Polypeptide specifically inhibiting cathepsin L
Patel et al. In vitro studies on the biosynthesis of rabbit C3: evidence for the synthesis of a nascent single chain precursor C3
WO1991012334A1 (en) Inhibitor of cytokine activity and applications thereof
JP5500749B2 (ja) 好中球刺激活性を有するポリペプチド
WO1993016715A1 (en) Fsf-1 and the early detection of fibrosis
JPS6339900A (ja) 精製ヒト脈管形成因子、その製造方法並びにそれを含有する医薬製剤
JPWO2001066734A1 (ja) 好中球刺激活性を有するポリペプチド
JPH02157298A (ja) 新規補体制御物質
WEICKER et al. Chemical and Antigenic Properties of a Human Erythrocyte Protein
Morrow The structure-function relationship of glucose-dependent insulinotropic polypeptide

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20031202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20040309

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20040408

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080416

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090416

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090416

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100416

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110416

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120416

Year of fee payment: 8

LAPS Cancellation because of no payment of annual fees